
    
      This is a non randomized, open label, single dose, parallel cohort, multisite study to
      investigate the effect of varying degrees of hepatic impairment on the plasma
      pharmacokinetics (total and unbound) of PF-05221304 after a single oral dose administered in
      the fed state.
    
  